Actelion's macitentan meets primary endpoint in pivotal Phase III study
Actelion announced that initial analysis indicates that the pivotal, long-term, event-driven study SERAPHIN with macitentan, a novel dual endothelin receptor antagonist, in 742 patients suffering from pulmonary arterial hypertension (PAH) and treated for up to three and a half years, has me ... more
Japan's Ministry of Health, Labour and Welfare grants approval for Actelion's miglustat for the treatment of Niemann-Pick type C disease
Actelion Ltd announced that Japan's Ministry of Health, Labour and Welfare has granted approval for miglustat for the treatment of Niemann-Pick type C disease.The approval was based on the data generated for the first approval of miglustat in this indication in the European Union, as well a ... more
Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. enter a collaboration agreement for XIAFLEX in Canada, Australia, Brazil and Mexico
Auxilium Pharmaceuticals, Inc. and Actelion Ltd. announced that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's co ... more